Thursday, October 30, 2025

5:30 PM-8:30 PM CT

Acute Leukemia & Myeloid Malignancies CME/CE Rounds Chicago
Crowne Plaza Chicago West Loop
Ballrooms A/B and C/D
25 South Halsted Street
Chicago, IL 60661
 
*Blood Cancer United will cover self-parking at the Crowne Plaza for practicing healthcare professionals only, upon submission of your completed evaluation and feedback form.
 
*Only one (1) person per medical technology/pharmaceutical company may register and attend the Rounds. A corporate email address is required.
 
Pre-registration is required. 

Agenda

5:30 PM – Dinner and networking
6:30 PM – Welcome, program overview, and updates in clinical trials
Himachandana Atluri
6:40 PM – Overview of Blood Cancer United resources
Lauren Berger
6:45 PM – Case presentation and discussion on the treatment of NPM1-mutated AML in an older, fit patient - intensive vs. non-intensive induction and consideration of menin inhibition
Noah Birch, Pierre Rodriguez, and Stephanie B. Tsai
7:15 PM – Case presentation and discussion on low-risk and high-risk MDS treatment
Max Kelsten, Melissa L. Larson, Amy Wang, and Sanja Zepcan
7:45 PM – Case presentation and discussion on CAR-T and ALL
Himachandana Atluri, Gregg Roloff, and Hannah Johnston
8:15 PM – Discussion and wrap-up
All Faculty
8:30 PM – Conclusion
Himachandana Atluri

Description

Interactive continuing medical education activity for healthcare professionals in Chicago and surrounding areas to discuss acute leukemia and myeloid malignancies updates and challenges in treatment.

Target Audience

This activity is intended for hematologists-oncologists, medical oncologists, physician associates, nurse practitioners, nurses and pharmacists involved in the care of patients with acute leukemia and myeloid malignancies. 

Learning Objectives

At the conclusion of this activity, participants will be better able to:
  • Explain the most recent data on novel treatment options in acute leukemias and myeloid malignancies
  • Discuss drug interactions with novel therapies and how to manage
  • Explain diagnostic and prognostic testing and challenges, relapse prevention and detection of measurable residual disease
  • Explain disparities and challenges in the diagnosis and treatment of acute leukemias and myeloid malignancies
  • Identify resources for patient education and support

Advisory Group

Himachandana Atluri, MD (Chair)
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
 
Taha Alrifai, MD
Advocate Health Care 
Park Ridge, IL
 
Jessica Altman, MD
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
 
Noah Birch, MD, PhD
University of Illinois Chicago (UIC)
Chicago, IL
 
Keriann Kordas, MSN, APN
The University of Chicago Medicine & Biological Sciences
Chicago, IL
 
Melissa L. Larson, MD
Rush University Medical Center
Chicago, IL
 
Adam Robinson, PharmD, BCOP
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
 

Gregory Roloff, MD
UChicago Medicine 
Chicago, IL

Stephanie B. Tsai, MD
Loyola University Medical Center
Maywood, IL

Olatoyosi Odenike, MD, FASCO
The University of Chicago 
Chicago, IL

Amy Wang, MD
Endeavor Health
Evanston, IL

Sanja Zepcan, PharmD, BCPS
Loyola University Medical Center
Maywood, IL

Faculty

Himachandana Atluri, MD (Chair)
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
Chicago, IL
 

Lauren Berger, MPH
Blood Cancer United
Washington, DC

Noah Birch, MD, PhD
University of Illinois Chicago (UIC)
Chicago, IL
 
Hannah Johnston, MD
UChicago Medicine 
Chicago, IL
 
Max Kelsten, MD
Northwestern University
Chicago, IL
 

Melissa L. Larson, MD
Rush University Medical Center
Chicago, IL

Pierre Rodriguez, MD 
John H. Stroger, Jr. Hospital of Cook County
Chicago, IL

Gregory Roloff, MD
UChicago Medicine 
Chicago, IL

Stephanie B. Tsai, MD
Loyola University Medical Center
Maywood, IL

Amy Wang, MD
Endeavor Health
Evanston, IL

Sanja Zepcan, PharmD, BCPS
Loyola University Medical Center
Maywood, IL

 

 
 
This activity is provided by Blood Cancer United and Medical Learning Institute Inc, in collaboration with the Association of Cancer Care Centers™ (ACCC).
 
 
 

Blood Cancer United thanks Autolus Therapeutics, Geron Corporation, and Novartis Pharmaceuticals Corporation for their financial support.

 

For questions, concerns, or assistance for people with disabilities or grievances, please contact us at: profeducation@LLS.org.

 

Follow Blood Cancer United